Afero has entered into a memorandum of understanding (MOU) agreement with Therma Bright Inc. The mutually beneficial partnership looks to bring Afero's innovation, security and tracking technology to Therma Bright's 15-minute COVID-19 rapid antigen screening solution. Upon completion, the proposed agreement will offer AcuVidTM COVID-19 Rapid Antigen Saliva Tests powered by Afero, with a goal to help communities safely and securely return to work and play using an embedded and encrypted technology for tracking and reporting AcuVID Tests for quality assurance, shipping, logistics, and point-of-care test results. It also paves the way for preparing the AcuVID COVID-19 Rapid Antigen Test for approval for at-home testing. The MOU was competed and signed on April 28, 2021. Both parties expect to complete a definitive agreement and begin work on or before June 1, 2021. Afero and its innovative solution was introduced to Therma Bright through Ridge Global, who saw an immediate need for serial testing to help slow the pandemic spread while providing accurate, secure reporting on testing results. Backed by the fifth largest IoT patent portfolio globally, the Afero Platform gives partners an agile development process, best-in-class security, and rapid data capture across multiple products and product generations. Afero's mobile application supports advanced quality control features and an intuitive user experience every single time a test is connected. With the secure Afero Cloud, AcuVidTM test status is tracked and managed on a real-time basis for many millions of tests deployed around the world. And with secure Afero Integrations, millions of test results can be shared with government agencies, workplaces, entertainment venues and more.